Response to the report, "A re-assessment of treatment with a tyrosine kinase inhibitor (imatinib) on tissue sparing and functional recovery after spinal cord injury" by Sharp et al.
Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.
Mathew B
MB
Abrams
Department of Medical Biochemisty and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden.
Ingrid
I
Nilsson
Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.
Jacob
J
Kjell
Department of Medical Biochemisty and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden.
Sebastian
S
Lewandowski
Department of Medical Biochemisty and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden.
Simone
S
Codeluppi
Department of Medical Biochemisty and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden.
Ulf
U
Eriksson
Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden. Electronic address: lars.olson@ki.se.
Lars
L
Olson
D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D005260:Female; D009416:Nerve Regeneration / Q000187:drug effects*; D010879:Piperazines / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D020127:Recovery of Function / Q000187:drug effects*; D013119:Spinal Cord Injuries / Q000188:drug therapy*; D001743:Urinary Bladder / Q000187:drug effects*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines